An alliance launched in March 2014 between Bristol-Myers Squibb (BMS) and Five Prime Therapeutics is due to expand, with a new Phase Ia/Ib study combining Nivolumab (Opdivo) with the monoclonal antibody FPA008 developed by Five Prime.
Five Prime received a $30 million payment from BMS toward the cancer combination study, involving multiple tumor types. The trial is expected to begin in 2015.
Nivolumab (Opdivo) is the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world (Japan).
Hossein Borghaei (Fox Chase) will present at the World NSCLC Summit on First line Nivolumab Treatment. Senior pharma professionals will be in attendance.